Dogwood Therapeutics Management
Management criteria checks 4/4
Dogwood Therapeutics' CEO is Greg Duncan, appointed in Apr 2020, has a tenure of 4.67 years. total yearly compensation is $566.92K, comprised of 93.3% salary and 6.7% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $6.60K. The average tenure of the management team and the board of directors is 4.7 years and 4 years respectively.
Key information
Greg Duncan
Chief executive officer
US$566.9k
Total compensation
| CEO salary percentage | 93.3% |
| CEO tenure | 4.7yrs |
| CEO ownership | 0.2% |
| Management average tenure | 4.7yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?
Aug 24
Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?
May 11Virios Therapeutics slides 11% postmarket on proposed stock offering
Sep 19Virios Therapeutics GAAP EPS of -$0.44 beats by $0.07
Aug 11Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation
Jun 25Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?
Mar 09Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?
Nov 02Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation
Jul 19Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study
Jun 04Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans
Mar 31Virios Therapeutics gains 10% on research deal in irritable bowel syndrome
Feb 01Virios Therapeutics prices IPO at $10
Dec 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$6m |
| Jun 30 2024 | n/a | n/a | -US$5m |
| Mar 31 2024 | n/a | n/a | -US$5m |
| Dec 31 2023 | US$567k | US$529k | -US$5m |
| Sep 30 2023 | n/a | n/a | -US$6m |
| Jun 30 2023 | n/a | n/a | -US$8m |
| Mar 31 2023 | n/a | n/a | -US$10m |
| Dec 31 2022 | US$937k | US$529k | -US$12m |
| Sep 30 2022 | n/a | n/a | -US$15m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$17m |
| Dec 31 2021 | US$1m | US$513k | -US$16m |
| Sep 30 2021 | n/a | n/a | -US$18m |
| Jun 30 2021 | n/a | n/a | -US$17m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | US$4m | US$375k | -US$10m |
Compensation vs Market: Greg's total compensation ($USD566.92K) is about average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Greg's compensation has been consistent with company performance over the past year.
CEO
Greg Duncan (59 yo)
4.7yrs
Tenure
US$566,923
Compensation
Mr. Gregory Duncan, also known as Greg, serves as Chief Executive Officer at Dogwood Therapeutics, Inc. (formerly known as Virios Therapeutics, Inc.), (formerly Virios Therapeutics, LLC) since April 01, 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 4.7yrs | US$566.92k | 0.17% $ 6.6k | |
| Founder & Member of Scientific Advisory Board | 12.9yrs | US$42.56k | 2.29% $ 87.4k | |
| Chief Financial Officer | less than a year | US$282.64k | 0.0090% $ 344.5 | |
| Chief Medical Officer | 12.9yrs | US$364.94k | 0% $ 0 | |
| Senior Vice President of Operations | 4.7yrs | US$425.03k | no data | |
| Chief Scientific Advisor | no data | no data | no data |
4.7yrs
Average Tenure
59yo
Average Age
Experienced Management: DWTX's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 6.9yrs | US$566.92k | 0.17% $ 6.6k | |
| Founder & Member of Scientific Advisory Board | less than a year | US$42.56k | 2.29% $ 87.4k | |
| Independent Director | 4yrs | US$57.56k | 0.0030% $ 114.7 | |
| Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board & Independent Director | 4yrs | US$55.56k | 0.0021% $ 80.3 | |
| Independent Director | 6.9yrs | US$64.06k | 0.038% $ 1.5k | |
| Independent Director | 4yrs | US$55.06k | 0.012% $ 459.2 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chair of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
4.0yrs
Average Tenure
68yo
Average Age
Experienced Board: DWTX's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 00:32 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dogwood Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sean Lee | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| David Bautz | Zacks Small-Cap Research |